Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2018 Financial Results and Recent Highlig...
May 01 2018 - 4:05PM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it
will host a conference call on Tuesday, May 8th, 2018 at 4:30 p.m.
Eastern Time to discuss corporate updates and financial results for
the first quarter ended March 31, 2018.
The call can be accessed by dialing (844) 296-7720 (U.S. and
Canada) or (574) 990-1148 (international) and entering passcode
9676198.
To access the live audio webcast, or the subsequent archived
recording, visit the "Investors and Media - Calendar of Events"
section of the Sunesis website at http://ir.sunesis.com. The
webcast will be recorded and available for replay on the company's
website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company developing
new therapeutics for the treatment of solid and hematologic
cancers. Sunesis has built an experienced cancer drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor vecabrutinib is
effective in ibrutinib-resistant chronic lymphocytic leukemia.
Vecabrutinib is currently being evaluated in a Phase 1b/2 study in
adults with chronic lymphocytic leukemia and other B-cell
malignancies who have progressed after prior therapies. Beyond the
development of vecabrutinib, the Company has two other kinase
inhibitor programs, including the Takeda-partnered pan-RAF
inhibitor TAK-580, which is in clinical trials for solid tumors,
and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which
is in preclinical development with an IND submission planned in
2019. PDK1 is a master kinase that activates other kinases
important to cell growth and survival including members of the AKT,
PKC, RSK and SGK families.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media
Inquiries: |
|
Maeve Conneighton |
Willie
Quinn |
Argot Partners |
Sunesis
Pharmaceuticals Inc. |
212-600-1902 |
650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024